In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
News|Podcasts|August 26, 2026
ACT Brief: Payment Infrastructure and Site Cash, Inspection Readiness Throughout Execution, and First Hemolytic Anemia Therapy
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine why payment inconsistency persists despite industry awareness, why inspection readiness must be built throughout execution not assembled at submission, and FDA approval of the first disease-specific treatment for a rare blood disorder.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part two of his interview , Patrick Mizer, chief technology officer at Ledger Run, traces fragmented contracts, outdated benchmarks, and disconnected systems behind payment inconsistency. With 80% of sites operating on six months or less of cash, the infrastructure redesign is urgent, and agentic AI is proving effective at removing manual invoice processing that historically consumed 60% of customer time. - In
part four of her series , Elizabeth Walsh, founder of Walsh Clinical Advisory, explained that inspection readiness is a continuous execution design condition, not a pre-submission activity, accumulating through proportionate risk-based decisions made by qualified personnel throughout the lifecycle. The TMF reflects how the program was actually run, not assembled before inspection; programs with active oversight, continuous self-review, and proactive gap management become inspection-ready through design and daily practice rather than remediation campaigns. - The
FDA approved Imaavy for warm autoimmune hemolytic anemia in patients 12 years and older who are corticosteroid-naive or experienced, marking the first therapy specifically approved for this rare, life-threatening autoantibody disease. The Phase II/III Energy trial showed three times as many Imaavy-treated patients achieved durable hemoglobin response by 24 weeks, with mean hemoglobin increase of one g/dL (grams per deciliter) at week one and 3.5-point higher mean fatigue reduction versus placebo.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
3
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
4
ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination
5